Qianjiang Yongan Pharmaceutical Co., Ltd. (SHE:002365)

SHE:002365 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	211.65	320.41	326.17	274.72	93.51	114.2
Trading Asset Securities	690.65	600.16	630.1	557.5	454.02	634.1
Cash & Short-Term Investments	902.3	920.57	956.27	832.22	547.53	748.3
Cash Growth	-0.40%	-3.73%	14.91%	52.00%	-26.83%	49.05%
Accounts Receivable	141.31	161.79	171.53	187.23	332.27	162.91
Other Receivables	3.83	6.14	6.33	8.12	11.63	10.57
Receivables	145.15	167.93	177.86	195.35	343.9	173.48
Inventory	90.32	93.5	69.9	149.6	145.78	81.67
Other Current Assets	17.41	16.66	9.57	18.18	28.69	24.11
Total Current Assets	1,155	1,199	1,214	1,195	1,066	1,028
Property, Plant & Equipment	937.95	948.07	953.61	1,022	988.96	989.6
Long-Term Investments	75.21	74.55	68.3	81.37	115.23	35.27
Goodwill	-	-	0.52	8.77	8.77	8.77
Other Intangible Assets	79.45	79.56	82.39	84.49	87.93	89.82
Long-Term Deferred Tax Assets	6.58	5.84	11.26	9.73	9.94	9.37
Other Long-Term Assets	1.22	1.93	17.46	22.03	9.21	3.35
Total Assets	2,256	2,309	2,347	2,424	2,286	2,164
Accounts Payable	120.16	124.02	160.65	162.77	114.91	97.58
Accrued Expenses	24.29	41.07	40.04	47.5	47	40.67
Short-Term Debt	29.5	39.53	10.01	40.01	20.38	122.35
Current Income Taxes Payable	5.78	7.06	7.84	0.61	2.37	2.25
Current Unearned Revenue	22.2	19.28	15.59	11.77	21.53	19.82
Other Current Liabilities	16.46	17.38	23.12	22.46	87.18	27.57
Total Current Liabilities	218.39	248.34	257.26	285.13	293.37	310.24
Long-Term Unearned Revenue	7	7.46	8.5	11.31	13.05	14.2
Long-Term Deferred Tax Liabilities	10.23	10.75	33.09	24.74	22.53	25.49
Total Liabilities	235.62	266.55	298.85	321.17	328.95	349.92
Common Stock	294.68	294.68	294.68	294.68	294.68	294.68
Additional Paid-In Capital	714.44	714.44	712.92	712.78	712.23	691.12
Retained Earnings	981.54	985.91	953.42	995.2	854.85	772.87
Treasury Stock	-40.48	-24.18	-	-	-	-3.79
Comprehensive Income & Other	23.94	22.94	22.89	14.71	4.16	0.84
Total Common Equity	1,974	1,994	1,984	2,017	1,866	1,756
Minority Interest	45.84	48.28	64.38	85.63	91.06	58.1
Shareholders' Equity	2,020	2,042	2,048	2,103	1,957	1,814
Total Liabilities & Equity	2,256	2,309	2,347	2,424	2,286	2,164
Total Debt	29.5	39.53	10.01	40.01	20.38	122.35
Net Cash (Debt)	872.8	881.04	946.26	792.2	527.15	625.95
Net Cash Growth	-2.47%	-6.89%	19.45%	50.28%	-15.78%	25.43%
Net Cash Per Share	2.98	2.99	3.21	2.69	1.84	2.17
Filing Date Shares Outstanding	289.15	289.15	294.68	294.68	294.68	294.28
Total Common Shares Outstanding	289.15	291.24	294.68	294.68	294.68	294.28
Working Capital	936.79	950.32	956.34	910.22	772.52	717.31
Book Value Per Share	6.83	6.85	6.73	6.85	6.33	5.97
Tangible Book Value	1,895	1,914	1,901	1,924	1,769	1,657
Tangible Book Value Per Share	6.55	6.57	6.45	6.53	6.00	5.63
Buildings	-	581.93	573.53	546.87	547.89	526.88
Machinery	-	1,306	1,268	1,210	1,083	1,039
Construction In Progress	-	66.41	26.12	51.55	43.07	4.47

Source: S&P Global Market Intelligence. Standard template. Financial Sources.